Sophion Bioscience, one of the leaders in the automated patch clamp field, has strengthened its team through the appointment of Damian Bell as Director of Scientific Affairs (starting October 1st, 2020).
Damian Bell brings nearly 25 years of ion channel drug discovery experience from world-leading academic, pharmaceutical, biotechnology and CRO labs. In his career, Damian worked at Eli Lilly, AstraZeneca, GSK, Convergence Pharmaceuticals, Charles River Laboratories, Iontas and Metrion Biosciences.
In his new position, Damian Bell will drive Sophion’s relationships with academia.
“This role gives me the opportunity to work with some of the best ion channel labs in the world, enabling them to do the best ion channel research on the QPatch and Qube, the best automated patch clamp technology in the world. If you’re a lab wanting to use automated patch clamp in innovative areas, in your next breakthrough, get in touch – Sophion want to be rocketing you to the stars,” said Damian Bell.
Damian’s appointment is the latest in a series of hires made by Sophion to support its continued growth. Previously, Sophion has added two more people to their team in Japan and hired two people in Denmark. At present, Sophion is seeking an Application Scientist in the US.
Photo by fauxels from Pexels